We’re thrilled to announce that our latest research paper, 𝘈𝘣𝘰𝘭π˜ͺ𝘴𝘩π˜ͺ𝘯𝘨 π˜™π˜¦π˜΅π˜³π˜°-π˜›π˜³π˜’π˜―π˜΄π˜₯𝘢𝘀𝘡π˜ͺ𝘰𝘯 𝘰𝘧 π˜—π˜³π˜°π˜₯𝘢𝘀𝘦𝘳 𝘊𝘦𝘭𝘭𝘴 π˜ͺ𝘯 π˜“π˜¦π˜―π˜΅π˜ͺ𝘷π˜ͺ𝘳𝘒𝘭 𝘝𝘦𝘀𝘡𝘰𝘳 π˜”π˜’π˜―π˜Άπ˜§π˜’π˜€π˜΅π˜Άπ˜³π˜ͺ𝘯𝘨, has been published in the journal Viruses..

In this paper, we address strategies to suppress the phenomenon of retro-transduction, a factor that decreases production efficiency in our lentiviral vector development and manufacturing processes.

Congratulations to all the authors, especially to the first co-authors Soledad BaΓ±os-Mateos and Carlos LΓ³pez.

As Marie Fertin, our Chief Technological Innovation Officer and the leader of the work shared with all of us, β€œthis publication is a recognition by our peers of the high scientific and innovative value of our work and contributes to the positioning of VIVEbiotech as a world-class CDMO”.

You can read the full article here: https://www.mdpi.com/1999-4915/16/8/1216

A huge thank you to everyone involved in this project.